The collaboration is centered around platform development and aims to develop a preclinical manufacturing platform, which will facilitate the generation of additional novel ViP-based product candidates for programs beyond VerImmune’s flagship Oncology program which is based on a First-in-Class immunotherapy approach known as Anti-tumor Immune Redirection (AIR).

Since its founding in 2020, VerImmune was originally solely based in the United States having offices and research laboratories at the JLABS@Washington DC incubator. In July 2023, VerImmune was awarded the Second Amgen X NSG Biolabs Golden Ticket Award which allowed the company to secure residency at NSG Biolabs to establish its presence within Asia-Pacific with Singapore as its new regional headquarters. The company intends to use these resources to build up a local platform development team.

“We believe that this collaboration focused on CMC has the potential to further advance and validate our ViP technology as a new modality bringing forth a new class of medicines.”  said Dr Joshua Wang, Founder and CEO of VerImmune Inc.  “As the saying goes ‘the Process is the Product. However, globally, there is only a handful of research institutes that focus on early-stage CMC development. This is critical for any asset’s eventual success but unfortunately often not prioritized part of product development. As we build our presence in Singapore, we recognize the potential of having BTI as a strategic research partner due to their deep expertise in bioprocessing and analytical sciences for biotherapeutics.”